AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Type 1 Diabetes Market Report 2019: T1D Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration - ResearchAndMarkets.com

December 3, 2019

DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--

The “Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration” report has been added to ResearchAndMarkets.com’s offering.

Type 1 diabetes (T1D) is a chronic condition that occurs as a result of the autoimmune destruction of pancreatic beta () cells, which are responsible for producing insulin, a hormone needed for body cells to allow for the absorption of glucose in order to produce energy.

Insulin is currently the mainstay treatment for T1D patients, and insulin therapy has significantly evolved over the last 90 years. Still, there is a pressing unmet need within T1D treatment landscape for more diverse, non-insulin disease-modifying pharmacotherapies (immunomodulatory or -cell preservation). T1D pipeline shows more diverse novel therapies under development. The report assesses first-in-class innovation within the pipeline for T1D.

Scope

Reasons to Buy

Key Topics Covered:

1. List of Tables & List of Figures

2 Type 1 Diabetes: Executive Summary

2.1 Current Therapies Leave High Unmet Needs in T1D Treatment Market

2.2 Pipeline Shows Shift Toward Disease-Modifying Approaches

2.3 Innovative First-in-Class Pipeline Products Hold Potential for Beta-Cell Regeneration Therapies

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification of T1D

4.2.1 Type 1 Diabetes

4.3 Sustained Innovation in T1D

4.4 Epidemiology for T1D

4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

5.1 Overview

5.2 Pipeline by Stage of Development and Molecule Type

5.3 Pipeline by Molecular Target

5.4 Comparative Distribution of Programs Between the T1D Market and Pipeline by Therapeutic Target Family

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class

5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs

5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline

6 First-in-Class Molecular Target Evaluation

6.1 Overview

6.2 Pipeline Programs Targeting Insulin

6.3 Pipeline Programs Targeting Natural Cytotoxicity Triggering Receptor

6.4 Pipeline Programs Targeting Interleukin

6.5 Pipeline Programs Targeting Follistatin-like

6.6 Pipeline Programs Targeting Interleukin

6.7 Pipeline Programs Targeting Interleukin 2 Receptor Beta

6.8 Pipeline Programs Targeting Macrophage Migration Inhibitory Factor

6.9 Pipeline Programs Targeting Nuclear Receptor Subfamily 5, Group A, Member

7 Key Players and Deals

7.1 Overview

7.1.1 Novo Nordisk Entered into a Licensing Agreement with reMYND

7.1.2 TetraGenetics Entered into a Co-development Agreement with LifeArc

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/vm0trp

View source version on businesswire.com:https://www.businesswire.com/news/home/20191203005550/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/03/2019 07:19 AM/DISC: 12/03/2019 07:19 AM

http://www.businesswire.com/news/home/20191203005550/en